Healthcare & pharmaceutical equity investment research

Healthcare Insights

Market cap

Date (published)

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Healthcare

13.06.23

ASCO 2023 key takeaways

Healthcare

thematic

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

Latest

Healthcare | Flash note

11.09.24

OSE Immunotherapeutics — Tedopi registrational study commences

Healthcare | Flash note

09.09.24

Basilea Pharmaceutica — H2 rewards continue: US$25m Cresemba milestone

Healthcare | Flash note

09.09.24

Oryzon Genomics — First patient dosed in new AML combination study

Healthcare | Flash note

05.09.24

IRLAB Therapeutics — New mesdopetam patent strengthens IP portfolio

insight

Healthcare

28.11.23

Incannex’s US redomicile is now complete – what’s next?

insight

Healthcare

20.11.23

Newron Pharmaceuticals: EKF 2023 QuickView

insight

Healthcare

08.09.23

VolitionRx – On the cusp of a breakthrough in testing for sepsis

insight

Healthcare

20.07.23

Incannex Healthcare: Is life better on Nasdaq?

insight

Healthcare

25.05.23

An update on OpGen: Deals, expansion and revenues

insight

Healthcare

18.05.23

Volition: Views from the sharp end

Equities

Region

Market cap

Actinogen Medical (ACW)

Latest price

AUD0.04

— 0.00 (0.00)

As at 16/09/2024

Market capitalisation: AUD98m

View equity

Flash note

Healthcare

27.08.24

Actinogen Medical — Further positive XanaCIDD results on depression

Update

Healthcare

22.08.24

Actinogen Medical — XanaCIDD data narrow the focus in depression

Flash note

Healthcare

28.06.24

Actinogen Medical — Publication of XanADu biomarker analysis

See more
content on

Actinogen Medical

AFT Pharmaceuticals (AFT)

Latest price

NZD3.23

▾ −0.09 (−2.71)

As at 16/09/2024

Market capitalisation: NZD339m

View equity

Flash note

Healthcare

09.08.24

AFT Pharmaceuticals — Hikma partnership expands to include Combogesic

Flash note

Healthcare

10.07.24

AFT Pharmaceuticals — Continued execution of footprint expansion

Update

Healthcare

23.05.24

AFT Pharmaceuticals — Growth underpinned by international momentum

See more
content on

AFT Pharmaceuticals

Argent Biopharma (RGT)

Latest price

GBP0.17

— 0.00 (0.00)

As at 16/09/2024

Market capitalisation: GBP9m

View equity

QuickView

Healthcare

05.09.24

Argent Biopharma — An innovative approach to drug development

Update

Healthcare

04.11.19

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

Update

Healthcare

10.07.19

MGC Pharmaceuticals — Initial CannEpil purchase orders received

See more
content on

Argent Biopharma

Basilea Pharmaceutica (BSLN)

Latest price

CHF44.85

▾ −0.80 (−1.75)

As at 16/09/2024

Market capitalisation: CHF591m

View equity

Flash note

Healthcare

09.09.24

Basilea Pharmaceutica — H2 rewards continue: US$25m Cresemba milestone

Flash note

Healthcare

28.08.24

Basilea Pharmaceutica — EU paediatric approval triggers CHF10m milestone

Flash note

Healthcare

22.08.24

Basilea Pharmaceutica — Another Cresemba milestone payment in the bank

See more
content on

Basilea Pharmaceutica

Cantargia (CANTA)

Latest price

SEK3.97

▾ 0.17 (4.47)

As at 16/09/2024

Market capitalisation: SEK729m

View equity

Flash note

Healthcare

19.04.23

Cantargia — Encouraging data for nadunolimab in CANFOUR

Flash note

Healthcare

14.03.23

Cantargia — First patient treated in Phase II part of TRIFOUR

Update

Healthcare

27.02.23

Cantargia — Next phase of clinical development in sight

See more
content on

Cantargia

Cereno Scientific (CRNO-B)

Latest price

SEK5.77

▾ −0.08 (−1.37)

As at 16/09/2024

Market capitalisation: SEK1,620m

View equity

Flash note

Healthcare

04.09.24

Cereno Scientific — CS1 granted OMPD, complementing FDA ODD

Update

Healthcare

02.09.24

Cereno Scientific — Pressing clinical assets forward to key inflection

Flash note

Healthcare

02.07.24

Cereno Scientific — CS1 Phase II results inbound; first dose of CS014

See more
content on

Cereno Scientific

Chosa (CHOSA)

Latest price

SEK1.09

▾ −0.02 (−1.80)

As at 16/09/2024

Market capitalisation: SEK77m

View equity

Update

Healthcare

02.06.23

Chosa Oncology — Making headway in precision oncology

Update

Healthcare

28.02.22

RhoVac — On the home straight

Outlook

Healthcare

14.10.21

RhoVac — Phase IIb BRaVac study results in H122

See more
content on

Chosa

Creo Medical (CREO)

Latest price

GBP0.29

▾ 0.35 (1.22)

As at 16/09/2024

Market capitalisation: GBP106m

View equity

Flash note

Healthcare

05.07.24

Creo Medical — Intuitive deal expansion is a notable milestone

Update

Healthcare

20.05.24

Creo Medical — Setting the stage for pivotal growth

Flash note

Healthcare

25.04.24

Creo Medical — NHS data validates Speedboat’s economic merit

See more
content on

Creo Medical

Immix Biopharma (IMMX)

Latest price

USD1.85

▾ −0.01 (−0.54)

As at 16/09/2024

Market capitalisation: USD51m

View equity

Update

Healthcare

14.08.24

Immix Biopharma — Full steam ahead with US CAR-T trial

Flash note

Healthcare

29.07.24

Immix Biopharma — US$8m grant to advance novel CAR-T treatment

Flash note

Healthcare

10.07.24

Immix Biopharma — US CAR-T trial commences patient dosing

See more
content on

Immix Biopharma

IRLAB Therapeutics (IRLAB-A)

Latest price

SEK13.35

— 0.00 (0.00)

As at 16/09/2024

Market capitalisation: SEK676m

View equity

Flash note

Healthcare

05.09.24

IRLAB Therapeutics — New mesdopetam patent strengthens IP portfolio

Update

Healthcare

11.07.24

IRLAB Therapeutics — Anticipation builds as inflection points approach

Flash note

Healthcare

03.07.24

IRLAB Therapeutics — Pirepemat passes Phase IIb DSMB safety hurdle

See more
content on

IRLAB Therapeutics

Medigene (MDG1)

Latest price

EUR1.13

▾ 0.03 (2.26)

As at 16/09/2024

Market capitalisation: EUR17m

View equity

Mendus (IMMU)

Latest price

SEK8.18

▾ 0.31 (3.94)

As at 16/09/2024

Market capitalisation: SEK412m

View equity

Update

Healthcare

27.08.24

Mendus — Broad progress across the pipeline

Flash note

Healthcare

24.07.24

Mendus — Collaboration unveils path forward for ilixadencel

Flash note

Healthcare

21.06.24

Mendus — Recent clinical data highlight vididencel’s potential

See more
content on

Mendus

MindMed (MNMD)

Latest price

USD6.36

▾ −0.09 (−1.40)

As at 16/09/2024

Market capitalisation: USD512m

View equity

Newron Pharmaceuticals (NWRN)

Latest price

CHF8.27

▾ 0.19 (2.35)

As at 16/09/2024

Market capitalisation: CHF158m

View equity

Flash note

Healthcare

26.06.24

Newron Pharmaceuticals — Evenamide road to registration and beyond

Flash note

Healthcare

14.05.24

Newron Pharmaceuticals — Evenamide potential for treatment of schizophrenia

Flash note

Healthcare

01.05.24

Newron Pharmaceuticals — Evenamide notches up another win (study 008A)

See more
content on

Newron Pharmaceuticals

Nicox (ALCOX)

Latest price

EUR0.15

— 0.00 (−1.30)

As at 16/09/2024

Market capitalisation: EUR10m

View equity

Flash note

Investment Companies

22.03.24

Henderson EuroTrust — Proposed merger with Henderson European Focus Trust

Flash note

Healthcare

18.12.23

Nicox — Animal data show favourable profile vs Lumigan

Update

Investment Companies

13.12.23

Henderson EuroTrust — Good stock selection outweighing headwinds

See more
content on

Nicox

OpGen (OPGN)

Latest price

USD2.20

▾ −0.04 (−1.79)

As at 16/09/2024

Market capitalisation: USD19m

View equity

Update

Healthcare

14.08.23

OpGen — Cash concerns dampen active Q2

Flash note

Healthcare

04.08.23

OpGen — FIND collaboration advances to development

Flash note

Healthcare

21.07.23

OpGen — Feasibility milestone from FIND collaboration

See more
content on

OpGen

Curated by Edison

singularityhub.com

The Next Step for AI in Biology Is to Predict How Proteins Behave in the Body

Healthcare

A new protein atlas can help turn static AI predictions of protein shapes into more fluid predictions of how proteins behave in the body.

Read article

www.genome.gov

The Cost of Sequencing a Human Genome

Healthcare

Estimated cost of sequencing the human genome over time since the Human Genome Project.

Read article

www.prnewswire.com

J.P. Morgan Launches New Life Sciences Private Capital Team Targeting Investments in Innovative Healthcare Companies

Healthcare

/PRNewswire/ -- J.P. Morgan Asset Management today announced the launch of a new life sciences private equity team, Life Sciences Private Capital. The new team...

Read article

insights.omnia-health.com

Leveraging nanotechnology to transform the disinfection industry

Healthcare

Co-founders of Kismet Technologies, Christina Drake and Shari Costantini, discuss how NanoRad, one of their flagship products, uses targeted application to kill a wide range of bacteria and viruses.

Read article

www.bain.com

2022 Healthcare Provider IT Report: Post-Pandemic Investment Priorities

Healthcare

As healthcare providers enter a new period of disruption, their software investment priorities present opportunities for vendors and investors.

Read article

Thematics

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

20.11.23

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

thematic

Healthcare

13.11.23

VolitionRx – Decoding the DNA of cancer

thematic

Healthcare

13.06.23

ASCO 2023 key takeaways

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

thematic

Healthcare

20.12.22

Cell and gene therapies

Equities

Equities by Sector

Sectors

Thematics

Latest

The art of measurement – Challenges in metrology

Vietnam Holding – Vietnam in the global digital race

US small-cap equities – Time to shine?

Audiovisual

Latest

Uncovering Trusts – BlackRock Latin American Investment Trust (BRLA)

The Biotech Growth Trust in 60 seconds

Take on Trusts – August

About Edison

About Edison

Careers

Healthcare

Sareum Holdings

5.66%

Healthcare Insights

Machine learning in drug development

ASCO 2023 key takeaways

Outlook for 2024: Life sciences – where has the conviction gone?

Latest

OSE Immunotherapeutics — Tedopi registrational study commences

Basilea Pharmaceutica — H2 rewards continue: US$25m Cresemba milestone

Oryzon Genomics — First patient dosed in new AML combination study

IRLAB Therapeutics — New mesdopetam patent strengthens IP portfolio

Incannex’s US redomicile is now complete – what’s next?

Newron Pharmaceuticals: EKF 2023 QuickView

VolitionRx – On the cusp of a breakthrough in testing for sepsis

Incannex Healthcare: Is life better on Nasdaq?

An update on OpGen: Deals, expansion and revenues

Volition: Views from the sharp end

Equities

Actinogen Medical (ACW)

AUD0.04

Actinogen Medical — Further positive XanaCIDD results on depression

Actinogen Medical — XanaCIDD data narrow the focus in depression

Actinogen Medical — Publication of XanADu biomarker analysis

See morecontent on

AFT Pharmaceuticals (AFT)

NZD3.23

AFT Pharmaceuticals — Hikma partnership expands to include Combogesic

AFT Pharmaceuticals — Continued execution of footprint expansion

AFT Pharmaceuticals — Growth underpinned by international momentum

See morecontent on

Argent Biopharma (RGT)

GBP0.17

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

MGC Pharmaceuticals — Initial CannEpil purchase orders received

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF44.85

Basilea Pharmaceutica — H2 rewards continue: US$25m Cresemba milestone

Basilea Pharmaceutica — EU paediatric approval triggers CHF10m milestone

Basilea Pharmaceutica — Another Cresemba milestone payment in the bank

See morecontent on

Cantargia (CANTA)

SEK3.97

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK5.77

Cereno Scientific — CS1 granted OMPD, complementing FDA ODD

Cereno Scientific — Pressing clinical assets forward to key inflection

Cereno Scientific — CS1 Phase II results inbound; first dose of CS014

See morecontent on

Chosa (CHOSA)

SEK1.09

Chosa Oncology — Making headway in precision oncology

RhoVac — On the home straight

RhoVac — Phase IIb BRaVac study results in H122

See morecontent on

Creo Medical (CREO)

GBP0.29

Creo Medical — Intuitive deal expansion is a notable milestone

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on